← Leaderboards
Dalton Robert Kim
Northwestern University
$196,104
Attributed
$196,104
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $50.1K · FY2018–22$100K$75K$50K$25K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$196,104 · 1
By mechanism
F31$196,104 · 1
Top collaborators
No co-investigators on record.
Most similar at Northwestern University
Same institution · by research overlap
- D. Martin Watterson$26,546,028
- Christopher Kuzawa$2,689,567
- Mary E Hunzicker-Dunn$6,958,293
- Xiaoyu Zhang$1,773,800
- Gary E Schiltz$5,645,620
Others in their field
Other Emerging Leaders on “Activity-Based Protein Profiling”
- Seungmin Hwang · University Of Chicago$4,418,311
- Casey John Krusemark · Purdue University$2,835,635
- Megan L Matthews · University Of Pennsylvania$2,535,999
- Pamela Vivian Chang · Cornell University$2,403,508
- Sara J Buhrlage · Dana-Farber Cancer Inst$1,555,478
- Brian George Dias · Emory University$1,478,414
Research focus
Activity-Based Protein ProfilingExhibitsBaseAcute Lymphocytic LeukemiaDna RepairCancer EtiologyCell LineCell ModelCessation Of LifeBindingAcute T Cell LeukemiaBiologicalClinically SignificantComparativeComputational ChemistryCovalent InteractionCysteineCytotoxicityDesignDisciplineDisease RemissionDisease ResistanceChemotherapyExperimental Study
Grant awards (4)
The design, synthesis, and characterization of potent and selective MEK7 inhibitors as targeted therapies for T-cell acute lymphoblastic leukemia$50,070
F31 · FY2022 · CA · contact PI
The design, synthesis, and characterization of potent and selective MEK7 inhibitors as targeted therapies for T-cell acute lymphoblastic leukemia$49,354
F31 · FY2021 · CA · contact PI
The design, synthesis, and characterization of potent and selective MEK7 inhibitors as targeted therapies for T-cell acute lymphoblastic leukemia$48,838
F31 · FY2020 · CA · contact PI
The design, synthesis, and characterization of potent and selective MEK7 inhibitors as targeted therapies for T-cell acute lymphoblastic leukemia$47,842
F31 · FY2018 · CA · contact PI